Drugs for macular degeneration
(Boston) Scientists from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the therapy of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is thought to bethe first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranibizuamab. Last October, these same scientists published early, six month outcomes of the same study, which also failed to show (Read more...)